Core Insights - Baird Medical is expanding its presence into San Francisco as part of its U.S. growth strategy, following its participation in the J.P. Morgan Health Conference [1] - The company has received FDA 510(k) clearance for its Microwave Ablation (MWA) technology, which has been successfully used to treat hundreds of patients, demonstrating significant recovery and positive outcomes [3] - Collaboration with medical specialists and comprehensive training initiatives are being implemented to enhance physician education and awareness of MWA technology [4] Company Overview - Baird Medical is a leader in minimally invasive microwave ablation technology, providing advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer [5] - The company is publicly traded on NASDAQ under the ticker BDMD and is focused on improving patient care through innovative medical devices [5] Market Recognition - Dr. Terrence K. Trapp, an otolaryngologist, has integrated Baird Medical's MWA system into his practice, indicating a growing interest in minimally invasive treatments for thyroid nodules [2] - Dr. Emad Kandil from Tulane University has performed over 100 MWA procedures, highlighting the clinical potential and increasing recognition of Baird Medical's innovations within the medical community [3]
Baird Medical Expands into San Francisco, Advancing U.S. Market Growth